Back to Search Start Over

Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis

Authors :
Richard P. Polisson
Frederick Wolfe
Eric P. Gall
Michael E. Weinblatt
Bruce Wall
Ralph E. Small
Sidney R. Block
Dennis Torretti
Robert Irby
Richard C. Merriman
Jon Coblyn
Sheldon D. Solomon
Joseph J. Biundo
Herbert Kaplan
Bernard F. Germain
Larry J. Anderson
Source :
Arthritis & Rheumatism. 33:330-338
Publication Year :
1990
Publisher :
Wiley, 1990.

Abstract

Weekly treatment with low-dose oral methotrexate (MTX) was compared with daily auranofin (AUR) treatment in a 36-week double-blind, randomized, multicenter study of 281 patients with active, adult-onset rheumatoid arthritis. Both treatment groups showed significant improvement by the usual measures of clinical efficacy. The response with MTX occurred earlier and was consistently greater than that with AUR. An intent-to-treat analysis showed significantly greater improvement (P < 0.01) with MTX for painful and swollen joint counts and physician and patient global assessments of disease activity. Adverse reactions were reported more frequently in the AUR group, and more AUR-treated patients were withdrawn from the study because of toxicity. MTX was thus more effective and better tolerated than AUR in this study.

Details

ISSN :
15290131 and 00043591
Volume :
33
Database :
OpenAIRE
Journal :
Arthritis & Rheumatism
Accession number :
edsair.doi...........adce3c4b5c803a0adcb16d2de8bd1595
Full Text :
https://doi.org/10.1002/art.1780330305